FN Media Group Presents GlobalInvestmentDaily.com Market Commentary
London – November 4, 2021 – The $11-trillion healthcare industry is going fully digital, disrupting industry giants & government monopolies, and finally giving the power back to the people. That means no more googling of symptoms for a panic-driven self-diagnosis… where a spot on the skin can turn into a rare fatal disease, or an upset stomach into Stage IV cancer. Mentioned in today’s commentary includes: Pfizer Inc (NYSE:PFE), Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Johnson & Johnson (NYSE:JNJ), Allergan plc (NYSE:AGN), Merck & Co. (NYSE:MRK).
The digital revolution in healthcare is about far more than simply scheduling an appointment with a clinic through an app …It’s about empowering the individual to take control of their health. It won’t be Google that leads this revolution. And it most certainly won’t be Cortana or Alexa.
CARA, the new AI-powered application developed to empower people to manage their own health care and diagnose health problems with expertise and proper follow-up, may be the answer to it all. And the company behind it is Canada-based Treatment.com International (TRUE; TREIF).
Artificial Intelligence Is Transforming Healthcare
For the past 6 years, a team of over 40 global world-class medical experts at Treatment.com International have been working to build some of the most sophisticated AI on the planet. It must be if it’s going to manage healthcare.
The CARA app serves as a health assessment and monitoring tool, with seamless integration of medical records and tests. It’s not gambling with google to diagnose your symptoms … it’s using your own medical history and a proper assessment of current symptoms.
CARA’s AI can optimize symptom assessment and diagnosis functions for patients and caregivers alike. The CARA app also offers a comprehensive health and wellness tracking and analytics platform that integrates seamlessly with wearables and should allow Treatment.com to capitalize on the multi-trillion-dollar wellness industry. The AI gets smarter as time goes on and has been meticulously designed to scale.
CARA doesn’t just assess your symptoms, give you personalized results based on your actual medical history, track your symptoms, and give you intelligent follow-up…It helps you understand what you really need to do next, and it monitors everything along the way.
Telemedicine Is The New Standard In Healthcare
The telemedicine market was worth about $42 billion in 2018. By 2026, it is set to hit nearly $400 billion. Americans are fed up with healthcare, and they’re fed up with spending more than any other country. On average, the US spends $10,000 a year per capita on health care.
That’s why we saw wellness apps downloaded 1.2 billion times in 2020 alone. The pandemic furthered the adoption of telemedicine exponentially, and now it’s not only here to stay—it’s here to disrupt, thoroughly. But “telehealth” is only one piece of the puzzle.
According to Allied Market Research, medical apps are projected to become far bigger. That’s bigger than the $400 billion value telemedicine is headed for. That’s where Treatment.com International Inc. (TRUE; TREIF) is laser focused.
TRUE brings it all together … from health assessments powered by AI to wellness products, TRUE has all the tools patients are looking for. TRUE also has all the tools insurance companies are looking for in a partner. Not only insurance companies, but also large corporations and potentially governments increasingly looking to offer health incentives to constituents.
The Real Value Goes Way Beyond This
Not only does TRUE, with help from the Global Library of Medicine, driving CARA, plan on positioning itself to attract a huge North American market of healthcare users, including Americans who are fed up with the system on multiple levels …
It’s also positioning itself to become an invaluable resource for a health insurance market that will be worth $4 trillion by 2027. Insurance companies want the predictability and scalability of something like TRUE’s AI.
Everyone is starting to understand the powers of AI, but we really haven’t seen anything yet. AI will likely revolutionize many industries, but many don’t understand how disruptive it can be in healthcare. We haven’t really seen anything yet.
Ultimately, what could catapult this into a multi-billion-dollar company is the underlying AI intellectual property, or IP. The AI is massive and it’s completely proprietary and 100% the property of Treatment.com. And AI on this scale could revolutionize every single industry … and healthcare is the ripest for revolution. We haven’t seen anything yet. This is just the beginning of the disruption of an $11-trillion industry, and the first to tie it all together in the most sophisticated offering stands to benefit most. That looks like Treatment.com International Inc. (TRUE; TREIF), and by the end of this year, the opportunity will be much clearer.
Big pharma is still making moves in the healthcare industry:
Pfizer Inc (NYSE:PFE) is a pharmaceutical company dedicated to research and development of innovative medicines, some of which are already used by millions of people. The company’s four primary businesses include: Pharmaceutical Products (R&D, manufacturing and sales), Consumer Healthcare (R&D, manufacturing and sales) Animal Health (R&D and sales) and Alliances/Licensing (licensing agreements for out-licensed products).
Pfizer took the spotlight during the COVID-19 pandemic as one of the leaders in the global vaccine race. The company’s innovative approach to medicine allowed it to achieve what was thought to be impossible just years ago. The vaccine rollout was one of the fastest and most widespread in history.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is a global pharmaceutical company that was founded in Jerusalem, Israel by Dr. Eliezer Dovid Romm and his son, Mr. Jacob Romm, an American Jew and graduate of the University of Pennsylvania’s Wharton School in Philadelphia. They wanted to create a business that would serve others with their innovative medications.
Teva Pharmaceutical Industries, largely due to its series of aggressive expansion and acquisitions has played a major role in helping patients get the treatment they need. In fact, its focus on generic, non-brand-name, medications have made treatment of depression more affordable than ever.
Johnson & Johnson (NYSE:JNJ) is another company that has received significant attention due to its COVID-19 vaccine, has also received widespread praise in the medical community. As one of the first approved vaccines, and the first one-dose vaccine, Johnson and Johnson was a dominant force in the healthcare realm over the past year and a half. But that’s only one aspect of the company’s massive business.
Johnson & Johnson is a pharmaceutical and medical device company that has been in business for more than 150 years. The company started out as a small family-owned business and now employs over 100,000 people around the world.
Allergan plc (NYSE:AGN) is a global pharmaceutical company that specializes in the research, development and commercialization of prescription medicines. The company has operations in more than 100 countries worldwide and markets its products to patients under brand names such as Botox®, Restasis, Juvederm® and other well-known brands.
Allergan plc’s success can be attributed to their team of scientists who are dedicated to making groundbreaking discoveries. They also maintain an open-door policy for all physicians so they can learn about their newest innovations firsthand. Another major key to the company’s success is its incredible patent moat.
Merck & Co. (NYSE:MRK) is a pharmaceutical company that has been in the industry for over 150 years and have made significant discoveries in vaccines, medicines, and animal health. They are most well-known for inventing the polio vaccine. Merck & Co., headquartered in Whitehouse Station, New Jersey, employs more than 22,000 people worldwide with about 8500 of those being based in the United States.
Merck & Co is a global leader in healthcare innovation with a mission to create innovative ways to improve lives. The company has been researching, developing, manufacturing and distributing prescription drugs for over the past century. Merck & Co.’s research efforts are focused on areas such as cancer, HIV/AIDS and Alzheimer’s disease.
By. Lori Stevenson
** IMPORTANT NOTICE AND DISCLAIMER — PLEASE READ CAREFULLY! **
PAID ADVERTISEMENT – GlobalInvestmentDaily.com and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Treatment.com International Inc. (“Treatment.com” or “Company”) to conduct investor awareness advertising and marketing. Treatment.com paid the Publisher four hundred and fifty thousand US dollars to produce and disseminate four articles profiling the Company. This compensation should be viewed as a major conflict with our ability to be unbiased.
Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur.
This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by Treatment.com) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.
SHARE OWNERSHIP. The Publisher owns shares and / or options of the featured company and therefore has an additional incentive to see the featured company’s stock perform well. The Publisher does not undertake any obligation to notify the market when it decides to buy or sell shares of the issuer in the market. The Publisher will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.
FORWARD LOOKING STATEMENTS. This publication contains forward-looking information which is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ from those projected in the forward-looking statements. Forward looking statements in this publication include, but are not limited to, the size and anticipated growth of the market for the companies’ products, the prospects for success of the Company’s to be launched health and wellness app – “CARA”, the reported scheduled release of CARA, the ability to acquire customers for CARA, and the projected growth and profit margins of the Company’s core product offerings. Factors that could cause results to differ include, but are not limited to, the companies’ ability to fund its capital requirements in the near term and long term, the management team’s ability to effectively execute its strategy, the degree of success of the launch of CARA, competition, market saturation, pricing pressures, etc. The forward-looking information contained herein is given as of the date hereof and we assume no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.
INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
INTELLECTUAL PROPERTY. GlobalInvestmentDaily.com is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.
DISCLAIMER: GlobalInvestmentDaily.com is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with GlobalInvestmentDaily.com or any company mentioned herein. The commentary, views and opinions expressed in this release by GlobalInvestmentDaily.com are solely those of GlobalInvestmentDaily.com and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact e-mail: email@example.com U.S. Phone: +1(954)345-0611